These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14697223)

  • 41. Factors governing intrinsic chemical reactivity differences between clavulanic and penicillanic acids.
    Lin YL; Chang NY; Lim C
    J Am Chem Soc; 2002 Oct; 124(40):12042-53. PubMed ID: 12358551
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.
    Skalweit MJ; Li M; Conklin BC; Taracila MA; Hutton RA
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1596-602. PubMed ID: 23318801
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-function analysis of alpha-helix H4 using PSE-4 as a model enzyme representative of class A beta-lactamases.
    Savoie A; Sanschagrin F; Palzkill T; Voyer N; Levesque RC
    Protein Eng; 2000 Apr; 13(4):267-74. PubMed ID: 10810158
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization.
    Bonomo RA; Liu J; Chen Y; Ng L; Hujer AM; Anderson VE
    Biochim Biophys Acta; 2001 Jun; 1547(2):196-205. PubMed ID: 11410275
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
    Weston GS; Blázquez J; Baquero F; Shoichet BK
    J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Modified Penicillin Molecule with Carbapenem-Like Stereochemistry Specifically Inhibits Class C β-Lactamases.
    Pan X; He Y; Chen T; Chan KF; Zhao Y
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [beta-Lactamase-inhibitor combinations].
    Nakano R; Okamoto R
    Nihon Rinsho; 2003 Mar; 61 Suppl 3():221-6. PubMed ID: 12717975
    [No Abstract]   [Full Text] [Related]  

  • 51. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe.
    Livermore DM; Yuan M
    J Antimicrob Chemother; 1996 Sep; 38(3):409-24. PubMed ID: 8889716
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolution of beta-lactamase inhibitors.
    Rolinson GN
    Surg Gynecol Obstet; 1991; 172 Suppl():11-6. PubMed ID: 2024221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E; Zissis NP; Constantoulaki S; Paniara O
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A kinetic study of NMC-A beta-lactamase, an Ambler class A carbapenemase also hydrolyzing cephamycins.
    Mariotte-Boyer S; Nicolas-Chanoine MH; Labia R
    FEMS Microbiol Lett; 1996 Sep; 143(1):29-33. PubMed ID: 8807798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition.
    Pagan-Rodriguez D; Zhou X; Simmons R; Bethel CR; Hujer AM; Helfand MS; Jin Z; Guo B; Anderson VE; Ng LM; Bonomo RA
    J Biol Chem; 2004 May; 279(19):19494-501. PubMed ID: 14757767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carbapenemase-producing Pseudomonas aeruginosa in UK.
    Woodford N; Palepou MF; Babini GS; Bates J; Livermore DM
    Lancet; 1998 Aug; 352(9127):546-7. PubMed ID: 9716067
    [No Abstract]   [Full Text] [Related]  

  • 57. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Unusual tazobactam-sensitive AmpC beta-lactamase from two Escherichia coli isolates.
    Babini GS; Danel F; Munro SD; Micklesen PA; Livermore DM
    J Antimicrob Chemother; 1998 Jan; 41(1):115-8. PubMed ID: 9511046
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.
    Brown RP; Aplin RT; Schofield CJ
    Biochemistry; 1996 Sep; 35(38):12421-32. PubMed ID: 8823177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.
    Prabhakaran K; Harris EB; Randhawa B; Hastings RC
    Microbios; 1995; 81(328):177-85. PubMed ID: 7752957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.